DDInter690 DDInter1622
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Rosuvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [simvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] This is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, rosuvastatin is considered the most potent; doses of 10 to 40mg rosuvastatin per day were found in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol.[A181409,A1793] However, the results of the SATURN trial concluded that despite this difference in potency, there was no difference in their effect on the progression of coronary atherosclerosis. Rosuvastatin is also a unique member of the class of statins due to its high hydrophilicity which increases hepatic uptake at the site of action, low bioavailability, and minimal metabolism via the Cytochrome P450 system. This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4, an enzyme involved in the metabolism of many commonly used drugs. Drugs such as [ciclosporin], [gemfibrozil], and some antiretrovirals are more likely to interact with this statin through antagonism of OATP1B1 organic anion transporter protein 1B1-mediated hepatic uptake of rosuvastatin.[F4649, F4652]
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may lead to a major life threatening interaction when taken with {v} Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is associated with {v} (Disease) coronary artery disease
coronary artery disease {u} (Disease) is treated by {v} (Compound) Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) regulates {v} (Gene) MVP
MVP {u} (Gene) is upregulated by {v} (Compound) Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Lopinavir
Lopinavir {u} may lead to a major life threatening interaction when taken with {v} Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) regulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Rosuvastatin
Ethanol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Pitavastatin
Pitavastatin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rosuvastatin
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound)
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may lead to a major life threatening interaction when taken with Rosuvastatin
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin
Ethanol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is associated with coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Rosuvastatin (Compound)
Ethanol (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Ethanol (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) regulates MVP (Gene) and MVP (Gene) is upregulated by Rosuvastatin (Compound)
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Lopinavir (Compound) and Lopinavir may lead to a major life threatening interaction when taken with Rosuvastatin
Ethanol (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) regulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Rosuvastatin (Compound)
Ethanol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pitavastatin (Compound) and Pitavastatin (Compound) resembles Rosuvastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin